We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




MicroRNA Maintains Cancer Cell Traits and Prompts Tumor Formation

By LabMedica International staff writers
Posted on 01 Jun 2017
A team of molecular biologists has determined that the microRNA mi-R-199a plays a critical role in breast tumor formation by helping to maintain the stem cell character of cancer stem cells and prevent them from differentiating into non-dividing cell types.

MicroRNAs (miRNAs) are a small noncoding family of 19- to 25-nucleotide RNAs that regulate gene expression by targeting messenger RNAs (mRNAs) in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complement between miRNAs and their targets. More...
Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer.

Tumor-initiating cells, or cancer stem cells (CSCs), possess stem-cell-like properties similar to those observed in normal adult tissue stem cells. Therefore, it is likely that normal and cancerous stem cells share regulatory mechanisms for maintaining self-renewing capacity and resisting differentiation elicited by molecular cues in the microenvironment.

Investigators at Princeton University reported in the May 22, 2017, online edition of the journal Nature Cell Biology that miR-199a promoted stem cell properties in normal mammary and breast cancer stem cells by directly repressing the nuclear receptor co-repressor LCOR (Ligand-dependent co-repressor), which primes interferon (IFN) responses. Elevated miR-199a expression in stem-cell-enriched populations protected normal and malignant stem-like cells from differentiation and senescence induced by IFNs that were produced by epithelial and immune cells in the mammary gland.

The ability of cancer stem cells to form tumors was enhanced by miR-199a. In contrast, increasing LCOR levels reduced the tumor-forming capacity of cancer stem cells. Breast cancer patients whose tumors expressed large amounts of miR-199a showed poor survival rates, whereas tumors with high levels of LCOR had a better prognosis.

"Interferons have been widely used for the treatment of multiple cancer types," said senior author Dr. Yibin Kang, professor of molecular biology at Princeton University. "These treatments might become more effective if the interferon-resistant cancer stem cells can be rendered sensitive by targeting the miR-199a-LCOR pathway."


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Automatic CLIA Analyzer
Shine i6000
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.